Previous close | 208.30 |
Open | 208.74 |
Bid | 0.00 x 1200 |
Ask | 0.00 x 800 |
Day's range | 206.75 - 209.93 |
52-week range | 177.63 - 276.43 |
Volume | |
Avg. volume | 263,398 |
Market cap | 9.768B |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | 27.39 |
EPS (TTM) | 7.57 |
Earnings date | 02 May 2024 |
Forward dividend & yield | 1.36 (0.66%) |
Ex-dividend date | 29 Feb 2024 |
1y target est | 264.50 |
WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com. An audio replay of the call will be availab
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significa